A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy

Inclusion Criteria: * Patient aged 50 to 85; * Obstructive or irritative urinary symptomatology linked to a BPH; * Score IPSS moderate to severe (8-19: moderate; 20-35: severe) or IPSS ≤ 7 in patient medically treated for symptomatic BPH; * Increase in prostate volume on the rectal touch or ultrasound; * Free consent, informed and written, dated and signed by the patient and the investigator (at the latest the day inclusion and before any examination requires the study); * Subject affiliate or beneficiary of a social protection Exclusion Criteria: * stenosis of the urethra confirmed by endoscopic or radiological examination; * prostate cancer suspicion; * medical past history of surgery, radiotherapy or pelvic trauma (, breach of the urethra, pubic symphysis disjunction); * surgical resection of the prostate (adenomecty); * clinical or paraclinical signs of vesical sphincterial disynergia; chronic urinary retention \> 500 ml; * BPH complications making surgery necessary: effects on the upper urinary tract: dilatation or renal obstructive insufficiency, bladder stones or diverticula. * patient previously treated by botulic toxin (whatever injection site); * Persons unable to understand the course of the study.